Pharmaceutical-Technology.com
Pharmaceutical-technology.com is part of a network of over 30 specialized B2B websites, reaching a vast global audience of active decision-makers, influencers, and thought leaders. Together, these platforms attract 55 million industry professionals each year. Being a part of GlobalData, we have access to an extensive database with over 1 billion data points that cover companies, deals, projects, forecasts, and trends. This wealth of information fuels our top-tier content. Our expertise spans more than 80 global markets and is supported by a dedicated team of over 800 award-winning journalists, researchers, and analysts, providing you with essential insights that can influence business outcomes. Our unique marketing solution combines award-winning targeting technology with our network of websites, offering a comprehensive approach that integrates insight, creativity, and advanced AI technology. This allows our clients to effectively identify, target, and engage with potential customers through access to our 30+ B2B media sites and their extensive sector-specific audiences. With unmatched reach, targeted data, and first-party data capabilities, we create outstanding campaigns for our clients. To learn more about our technology-driven marketing solution, please visit https://www.verdictmediastrategies.com/.
Outlet metrics
Global
#231255
United States
#146838
Health/Pharmacy
#295
Articles
-
6 days ago |
pharmaceutical-technology.com | Jenna Philpott
The agreement adds to Eli Lilly’s growing portfolio of AI-enabled drug discovery partnerships. Eli Lilly will use BigHat’s AI-driven Milliner platform. Credit: Just_Super via Getty Images. Eli Lilly has signed a new research deal with BigHat Biosciences to co-develop next-generation antibody therapeutics, as the pharma company continues to expand its capabilities in artificial intelligence (AI)-driven drug development.
-
1 week ago |
pharmaceutical-technology.com | Jenna Philpott
Bluebird bio (bluebird) has reaffirmed its support for a proposed acquisition by Carlyle and SK Capital after rival bidder Ayrmid failed to deliver a binding offer or secure financing by the extended deadline. The announcement marks the second time Ayrmid has initiated discussions with bluebird without producing a fully financed proposal.
-
1 week ago |
pharmaceutical-technology.com | Robert Barrie
Skip to site menuSkip to page content Pharmaceutical companies are demanding changes in European regulation as looming tariffs implemented by US President Donald Trump “threaten” billions of planned pharma investments on the continent.
-
1 week ago |
pharmaceutical-technology.com | Jenna Philpott
Skip to site menuSkip to page content Glycomine has raised $115m in Series C financing to advance its lead investigational therapy, GLM101, into a Phase IIb clinical trial for an ultra-rare disorder. GLM101 is being developed as a treatment for phosphomannomutase-2 congenital disorder of glycosylation (PMM2-CDG), a rare and life-threatening genetic disorder with no approved treatments.
-
1 week ago |
pharmaceutical-technology.com | Robert Barrie
Skip to site menuSkip to page content Member states of the World Health Organization (WHO) have reached an agreement on how to tackle future pandemics courtesy of a new treaty that will facilitate international collaboration and shared response efforts. The draft agreement, which will be put forth at an upcoming World Health Assembly in May, comes after three years of negotiations between governments.
Pharmaceutical-Technology.com journalists
Contact details
Address
123 Example Street
City, Country 12345
Phone
+1 (555) 123-4567
Email Patterns
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →